Literature DB >> 25740413

Molecular interaction of α-conotoxin RgIA with the rat α9α10 nicotinic acetylcholine receptor.

Layla Azam1, Athanasios Papakyriakou2, Marios Zouridakis2, Petros Giastas2, Socrates J Tzartos2, J Michael McIntosh2.   

Abstract

The α9α10 nicotinic acetylcholine receptor (nAChR) was first identified in the auditory system, where it mediates synaptic transmission between efferent olivocochlear cholinergic fibers and cochlea hair cells. This receptor gained further attention due to its potential role in chronic pain and breast and lung cancers. We previously showed that α-conotoxin (α-CTx) RgIA, one of the few α9α10 selective ligands identified to date, is 300-fold less potent on human versus rat α9α10 nAChR. This species difference was conferred by only one residue in the (-), rather than (+), binding region of the α9 subunit. In light of this unexpected discovery, we sought to determine other interacting residues with α-CTx RgIA. A previous molecular modeling study, based on the structure of the homologous molluscan acetylcholine-binding protein, predicted that RgIA interacts with three residues on the α9(+) face and two residues on the α10(-) face of the α9α10 nAChR. However, mutations of these residues had little or no effect on toxin block of the α9α10 nAChR. In contrast, mutations of homologous residues in the opposing nAChR subunits (α10 Ε197, P200 and α9 T61, D121) resulted in 19- to 1700-fold loss of toxin activity. Based on the crystal structure of the extracellular domain (ECD) of human α9 nAChR, we modeled the rat α9α10 ECD and its complexes with α-CTx RgIA and acetylcholine. Our data support the interaction of α-CTx RgIA at the α10/α9 rather than the α9/α10 nAChR subunit interface, and may facilitate the development of selective ligands with therapeutic potential.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25740413      PMCID: PMC4407738          DOI: 10.1124/mol.114.096511

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  58 in total

1.  Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity.

Authors:  V T Nguyen; A Ndoye; S A Grando
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  A novel alpha-conotoxin, PeIA, cloned from Conus pergrandis, discriminates between rat alpha9alpha10 and alpha7 nicotinic cholinergic receptors.

Authors:  J Michael McIntosh; Paola V Plazas; Maren Watkins; María E Gomez-Casati; Baldomero M Olivera; A Belén Elgoyhen
Journal:  J Biol Chem       Date:  2005-06-27       Impact factor: 5.157

3.  Onset of cholinergic efferent synaptic function in sensory hair cells of the rat cochlea.

Authors:  Isabelle Roux; Eric Wersinger; J Michael McIntosh; Paul A Fuchs; Elisabeth Glowatzki
Journal:  J Neurosci       Date:  2011-10-19       Impact factor: 6.167

4.  A transient calcium-dependent chloride current in the immature Xenopus oocyte.

Authors:  M E Barish
Journal:  J Physiol       Date:  1983-09       Impact factor: 5.182

5.  Functional characterization of alpha9-containing cholinergic nicotinic receptors in the rat adrenal medulla: implication in stress-induced functional plasticity.

Authors:  Claude Colomer; Luis A Olivos-Oré; Anne Vincent; J Michael McIntosh; Antonio R Artalejo; Nathalie C Guérineau
Journal:  J Neurosci       Date:  2010-05-12       Impact factor: 6.167

6.  Characterization of the human nicotinic acetylcholine receptor subunit alpha (alpha) 9 (CHRNA9) and alpha (alpha) 10 (CHRNA10) in lymphocytes.

Authors:  Huashan Peng; Robert L Ferris; Tonya Matthews; Hakim Hiel; Andres Lopez-Albaitero; Lawrence R Lustig
Journal:  Life Sci       Date:  2004-12-03       Impact factor: 5.037

7.  alpha-Conotoxin EI, a new nicotinic acetylcholine receptor antagonist with novel selectivity.

Authors:  J S Martinez; B M Olivera; W R Gray; A G Craig; D R Groebe; S N Abramson; J M McIntosh
Journal:  Biochemistry       Date:  1995-11-07       Impact factor: 3.162

Review 8.  Mammalian nicotinic acetylcholine receptors: from structure to function.

Authors:  Edson X Albuquerque; Edna F R Pereira; Manickavasagom Alkondon; Scott W Rogers
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

9.  Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice.

Authors:  Outi Salminen; Karen L Murphy; J Michael McIntosh; John Drago; Michael J Marks; Allan C Collins; Sharon R Grady
Journal:  Mol Pharmacol       Date:  2004-06       Impact factor: 4.436

10.  Nicotinic acetylcholine receptor subtypes in nociceptive dorsal root ganglion neurons of the adult rat.

Authors:  Rainer Viktor Haberberger; Nadia Bernardini; Michaela Kress; Petra Hartmann; Katrin Susanne Lips; Wolfgang Kummer
Journal:  Auton Neurosci       Date:  2004-06-30       Impact factor: 3.145

View more
  19 in total

1.  Cloning, synthesis, and characterization of αO-conotoxin GeXIVA, a potent α9α10 nicotinic acetylcholine receptor antagonist.

Authors:  Sulan Luo; Dongting Zhangsun; Peta J Harvey; Quentin Kaas; Yong Wu; Xiaopeng Zhu; Yuanyan Hu; Xiaodan Li; Victor I Tsetlin; Sean Christensen; Haylie K Romero; Melissa McIntyre; Cheryl Dowell; James C Baxter; Keith S Elmslie; David J Craik; J Michael McIntosh
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

Review 2.  α-Conotoxins active at α3-containing nicotinic acetylcholine receptors and their molecular determinants for selective inhibition.

Authors:  Hartmut Cuny; Rilei Yu; Han-Shen Tae; Shiva N Kompella; David J Adams
Journal:  Br J Pharmacol       Date:  2017-06-11       Impact factor: 8.739

3.  Pain therapeutics from cone snail venoms: From Ziconotide to novel non-opioid pathways.

Authors:  Helena Safavi-Hemami; Shane E Brogan; Baldomero M Olivera
Journal:  J Proteomics       Date:  2018-05-16       Impact factor: 4.044

4.  Discovery of peptide ligands through docking and virtual screening at nicotinic acetylcholine receptor homology models.

Authors:  Abba E Leffler; Alexander Kuryatov; Henry A Zebroski; Susan R Powell; Petr Filipenko; Adel K Hussein; Juliette Gorson; Anna Heizmann; Sergey Lyskov; Richard W Tsien; Sébastien F Poget; Annette Nicke; Jon Lindstrom; Bernardo Rudy; Richard Bonneau; Mandë Holford
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-05       Impact factor: 11.205

5.  αS-conotoxin GVIIIB potently and selectively blocks α9α10 nicotinic acetylcholine receptors.

Authors:  Sean B Christensen; Pradip K Bandyopadhyay; Baldomero M Olivera; J Michael McIntosh
Journal:  Biochem Pharmacol       Date:  2015-06-11       Impact factor: 5.858

6.  Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain.

Authors:  Haylie K Romero; Sean B Christensen; Lorenzo Di Cesare Mannelli; Joanna Gajewiak; Renuka Ramachandra; Keith S Elmslie; Douglas E Vetter; Carla Ghelardini; Shawn P Iadonato; Jose L Mercado; Baldomera M Olivera; J Michael McIntosh
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-21       Impact factor: 11.205

7.  Therapeutic concentrations of varenicline in the presence of nicotine increase action potential firing in human adrenal chromaffin cells.

Authors:  Arik J Hone; J Michael McIntosh; Lola Rueda-Ruzafa; Juan Passas; Cristina de Castro-Guerín; Jesús Blázquez; Carmen González-Enguita; Almudena Albillos
Journal:  J Neurochem       Date:  2016-12-09       Impact factor: 5.372

8.  αO-Conotoxin GeXIVA disulfide bond isomers exhibit differential sensitivity for various nicotinic acetylcholine receptors but retain potency and selectivity for the human α9α10 subtype.

Authors:  Dongting Zhangsun; Xiaopeng Zhu; Quentin Kaas; Yong Wu; David J Craik; J Michael McIntosh; Sulan Luo
Journal:  Neuropharmacology       Date:  2017-04-14       Impact factor: 5.250

Review 9.  Understanding structure-function relationships of the human neuronal acetylcholine receptor: insights from the first crystal structures of neuronal subunits.

Authors:  Petros Giastas; Marios Zouridakis; Socrates J Tzartos
Journal:  Br J Pharmacol       Date:  2017-06-20       Impact factor: 8.739

10.  Development of Conformationally Constrained α-RgIA Analogues as Stable Peptide Antagonists of Human α9α10 Nicotinic Acetylcholine Receptors.

Authors:  Nan Zheng; Sean B Christensen; Alan Blakely; Cheryl Dowell; Landa Purushottam; J Michael McIntosh; Danny Hung-Chieh Chou
Journal:  J Med Chem       Date:  2020-07-16       Impact factor: 8.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.